What are the antihypertensive agents of choice for an infant (≤12 months) with renovascular hypertension?

Antihypertensive Agents of Choice in Infants with Renovascular Hypertension

ACE inhibitors (specifically captopril or enalapril) are the antihypertensive agents of choice for infants with renovascular hypertension, as they directly target the renin-angiotensin system that is pathophysiologically activated in renovascular disease.

Primary Recommendation

For infants ≤12 months with renovascular hypertension, ACE inhibitors should be the first-line pharmacologic therapy 1. The guideline evidence supports ACE inhibitors as Grade C recommended monotherapy for children with secondary hypertension 1. While these guidelines address "children" broadly, the specific research evidence demonstrates successful use of ACE inhibitors in the neonatal and infant population with renovascular hypertension.

Specific ACE Inhibitor Options for Infants:

• Captopril (oral): Doses of 0.1-0.2 mg/kg/day have achieved blood pressure reduction in neonates with renovascular hypertension refractory to other agents 2. This is particularly effective for renovascular causes 2.

• Enalapril (intravenous): Successfully used in term neonates with severe renovascular hypertension refractory to standard medical therapy 3. This option is valuable when oral administration is not feasible.

Rationale for ACE Inhibitors in Renovascular Hypertension

The pathophysiology of renovascular hypertension involves activation of the renin-angiotensin-aldosterone system due to reduced renal perfusion. ACE inhibitors directly interrupt this mechanism, making them mechanistically superior to other antihypertensive classes for this specific etiology. Case reports demonstrate prompt blood pressure response to captopril in infants with renovascular disease 4, confirming the pathophysiologic rationale.

Alternative Agents

While guidelines recommend three first-line options for pediatric hypertension generally 1:

1. ACE inhibitors (Grade C)
2. ARBs (Grade C)
3. Long-acting dihydropyridine calcium channel blockers (Grade D)

For renovascular hypertension specifically in infants, ACE inhibitors remain preferred due to:

• Direct mechanism of action on the activated renin-angiotensin system
• Established safety data in neonates and infants 3, 2
• Documented efficacy when other agents fail 2

Calcium channel blockers (such as nifedipine or amlodipine) are commonly prescribed in children due to low adverse-effect profiles 5, but lack the specific mechanistic advantage in renovascular disease.

Critical Monitoring Considerations

Monitor renal function closely when initiating ACE inhibitors in infants with renovascular hypertension. One case report documented elevated serum urea, creatinine, potassium, and phosphorus with high-dose captopril (5 mg/kg), which resolved after discontinuation 2. This emphasizes:

• Start with lower doses (0.1-0.2 mg/kg/day for captopril)
• Monitor electrolytes and renal function within days of initiation
• Be prepared to adjust or discontinue if renal function deteriorates

Management Algorithm

1. Confirm renovascular hypertension diagnosis using Doppler ultrasound initially, followed by ACE inhibitor renography if needed 6

2. Initiate ACE inhibitor monotherapy:

   • Oral captopril 0.1-0.2 mg/kg/day (if oral route available)
   • IV enalapril (if oral route not feasible or severe hypertension)

3. Monitor within 48-72 hours: Blood pressure response, serum creatinine, potassium, urea

4. Titrate dose if inadequate response and renal function stable

5. Refer to pediatric hypertension specialist if blood pressure goals not achieved with standard-dose monotherapy for 6 months 1

6. Consider definitive intervention: Medical management should temporize until infant is large enough for angiography and potential angioplasty 6, or surgical intervention if indicated 7

Important Caveats

• Bilateral renal artery disease: ACE inhibitors may precipitate acute kidney injury if bilateral stenosis present; use with extreme caution and close monitoring
• Accessory renal arteries: May be missed on initial imaging 6, potentially explaining inadequate response to therapy
• Target blood pressure: Aim for <95th percentile, or <90th percentile if target organ damage present 1
• Underlying cause treatment: Pharmacologic therapy is often temporizing; definitive treatment of the renovascular lesion (endovascular or surgical) should be pursued by pediatric hypertension experts 1, 7